A pharmacogenetics test is a one-time genetic test performed after obtaining a simple buccal swab from a patient and can reveal variability in the expression of the cytochrome P450 enzymes that are involved in metabolizing 90% of medications prescribed in the U.S.

This knowledge may help providers when making personalized therapeutic decisions for patients suffering from some of the most prevalent clinical conditions like psychiatric disorders, cardiovascular disease or pain.

ITS ALL ABOUT IMPROVING OUTCOMES.

AVOID ADVERSE SIDE EFFECTS

Adverse Drug Reactions (ADRs) are the 4th leading cause of death in America. 4.5 million Americans visit their doctor’s office or the emergency room every year because of adverse side effects related to prescription medications.

IMPROVE MEDICATION EFFECTIVENESS

53% of medications are ineffective as the first line of therapy. Choosing the right dose of the right medication through genetic testing may drastically improve the treatment outcome.

SAVE TIME AND MONEY

Billions of dollars are spent annually on medications that do not work. PGx testing is a noninvasive buccal swab that is only tested once, but offers guidance for a lifetime

IMPROVE PATIENT SATISFACTION

Avoid the trial-and-error pattern of prescribing. Patients who experience medication side effects are less likely to maintain medication compliance.

THE CYTOCHROME P450 SYSTEM
TESTING MENU

Individual Genes Tested

  • Comprehensive Panel—APOE, COMT, CYPlA2, CYP2B6, CYP2Cl9, CYP2C9, CYP2D6, CYP3A4, CYP3A5, MTHFR, VKORCl, Factor II, Factor V, SLCOlBl
  • Cardiac Panel—APOE, CYP2Cl9, CYP2C9, CYP2D6, CYP3A4, CYP3A5, MTHFR, VKORCl, Factor II, Factor V, SLCOl Bl
  • Psych Panel—COMT, CYPlA2, CYP2B6, CYP2Cl9, CYP2C9, CYP2D6, CYP3A4, CYP3A5, MTHFR
  • Pain Panel—COMT, CYPlA2, CYP2B6, CYP2Cl9, CYP2C9, CYP2D6, CYP3A4, CYP3A5

BODY SYSTEMS AFFECTED BY PHARMACOGENOMIC BIOMARKERS

MEDICATION CLASSES AFFECTED BY PHARMACOGENOMIC BIOMARKERS

  • Anti-infectives (antibiotics, antifungals, anthelmintics, antimalarials, antiprotozoals, antivirals)
  • Antineoplastics (antifolates, purine analogies, pyrimidine analogues)
  • Cardiovascular Drugs (anticoagulants, anti-hypertensives, cholesterol-lowering agents, anti-anginals, antiarrhythmics)
  • Central Nervous System Drugs (sedatives, hypnotics and tranquilizers, amphetamines, caffeine)
  • Gastrointestinal Drugs (antacids, proton pump inhibitors, histamine2 blockers, promotility agents)
  • Immunological Agents (calcineurin inhibitors, interleukin inhibitors, other immunosuppressants)
  • Metabolic Agents (anti-diabetic agents, antigout agents, antihyperlipidemic agents, misc.)
  • Oncological Agents (antiestrogens, alkylating agents, others)

Case Review

Patient History
85-year-old female patient with history of depression and known factor 5 variant
Symptoms/disease state
Patient was not eating, became very disengaged in conversation, needed a walker for the first time for stability
Why Test was Ordered
Family changed primary care physician for the patient and new physician ordered the test as a starting point to identify what might be occurring
Outcome
PGX report identified anti-depressant medication was not one the patient could take. Changed medication and patient no longer needed walker and became vibrant and engaged within 2 weeks of med change
Previous
Next

For More Info

Fill out the form below to get a quick, reliable answer.

  • This field is for validation purposes and should be left unchanged.

Fill out the form below to get a quick, reliable answer.

  • This field is for validation purposes and should be left unchanged.